Beta-2 microglobulin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Michal Harel (talk | contribs) New page: {{STRUCTURE_3mrb| PDB=3mrb | SIZE=400| SCENE=Cadherin/Cv/1 |right|CAPTION=Human β-2 microglobulin complex with MHC I and HCMV PP65 nonapeptide, 3mrb }} '''Beta-2 microglobulin''' (... |
Michal Harel (talk | contribs) No edit summary |
||
| (62 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='350' side='right' scene='45/459284/Cv/1' caption='Human β-2 microglobulin (green) complex with MHC I (magenta) and HCMV PP65 nonapeptide (cyan), [[3mrb]]'> | |||
[[Beta-2 microglobulin]] ('''B2M''') is a component of MHC class I system. B2M associates with MHC class I α chain, CD1 and Qa. Loss of B2M function causes iron excess. <ref>PMID:21131979</ref> For more details, see: [[Human beta two microglobulin]] and [[Molecular playground/beta 2 microglobulin]]. | |||
<br/> | |||
[[Image:MHC Class 1.png|thumb|200px|left|Diagram of MHC I Complex]] | |||
{{Clear}} | |||
== Disease == | |||
Elevated B2M levels are found in patients of liver cirrhosis<ref>PMID:3884477</ref> and hepatitis<ref>PMID:29221492</ref>. Dialysis-associated amyloidosis is a serious complication in chronic dialysis patients. It is caused by B2M fibrils amyloid deposits<ref>PMID:10737162</ref>. | |||
== Relevance == | |||
B2M is used as a marker for certain types of blood cell cancer. It can indicate the spread and severity of myeloma. | |||
== Structural Highlights == | |||
<scene name='45/459284/Cv/2'>Human β-2 microglobulin with MHC class I HLA-A2 and HCMV PP65 nonapeptide</scene> ([[3mrb]]). | |||
== 3D Structures of β-2 microglobulin == | == 3D Structures of β-2 microglobulin == | ||
[[Beta-2 microglobulin 3D structures]] | |||
</StructureSection> | |||
== References == | |||
<references/> | |||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Latest revision as of 08:10, 26 February 2020
| ||||||||||||
References
Proteopedia Page Contributors and Editors (what is this?)
Michal Harel, Alexander Berchansky, David Canner, Joel L. Sussman
